Glaxosmithkline Share News (GSK)

GSK's Nigerian unit says Q1 pretax profit falls 53 pct

LAGOS, April 30 (Reuters) - GSK's Nigerian unit said on Thursday its first-quarter pretax profit fell 52.7 percent to 421.83 million naira ($2 million), from a year earlier. Revenue also fell to 7.45 billion naira in the period to end-March from 7.80 billion naira last year, the pharmaceut

AGM, EGM Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Wednesday broker round-up

Sky: JP Morgan reiterates neutral stance and 1,170p target. GlaxoSmithKline: UBS reiterates buy and 1,700p target. StanChart: Nomura reiterates neutral and lifts target to 1,170p from 1,030p. UBS reiterates neutral stance with 1,000p target. Henderson Group: Citi reiterates buy with 3,250p target.

Earnings, Trading Statements Calendar - Week Ahead

LONDON MARKET COMMENT: Stocks Seen Up Ahead Of US GDP, Fed Decision

LONDON MARKET COMMENT: Stocks Called To Rebound With US Fed In Focus

Earnings, Trading Statements Calendar - Week Ahead

Biotechs seek cross-over to public markets

By Robert Sherwood NEW YORK, April 28 (IFR) - Early-stage biotech companies continue to find a favorable bid in both the private and public markets. Continuing the trend of late-stage crossover rounds, Adaptimmune Therapeutics and aTyr Pharma are looking to follow up recent private institut

LONDON MARKET CLOSE: FTSE 100 Reverses Three Days Of Gains

Earnings, Trading Statements Calendar - Week Ahead

GSK shingles vaccine shows benefits across all age groups

LONDON, April 28 (Reuters) - An experimental shingles vaccine from GlaxoSmithKline is effective across all age groups, researchers said on Tuesday, boosting the prospects of a key product in the British drugmaker's development pipeline. In contrast to Merck's established Zostavax, currently

GlaxoSmithKline Gets Positive Data Late Stage Shingles Vaccine Trial

LONDON MARKET COMMENT: Stocks Lower As UK GDP Misses Expectations